Category Archives: Ulcerative Colitis

Up to 25,000 people with ulcerative colitis (UC) in England could be in line for treatment with Pfizers once-daily oral therapy Velsipity, after NICE recommended its use by the NHS. The new guidance emerged on the same day that Velsipity (etrasimod) was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as a treatment for moderately to severely active UC, a few weeks after it was cleared by the European Commission. Continue reading →

Thousands of people could be set to benefit after NICE today (Monday, 11 March) recommended a new one-a-day pill as an option for treating severe ulcerative colitis. NICEs final guidance on etrasimod (also known as Velsipity and made by Pfizer) is being published on the same day that the treatment was granted a licence by the Medicines and Healthcare Products Regulatory Agency (MHRA). Just over 25,000 people in England are eligible to receive the new treatment, which was evaluated using a simpler technology appraisal process. Continue reading →

A new once-a-day pill has been recommended as an option for treating severe ulcerative colitis in England, with thousands of patients set to be eligible. The National Institute for Health and Care Excellence (NICE) has published final guidance backing the treatment etrasimod (Velsipity) We are determined to continue getting the best care to patients fast Helen Knight The move, on Monday, came on the same day that etrasimod was granted a licence by the Medicines and Healthcare Products Regulatory Agency (MHRA). Continue reading →

Pfizer Inc. Continue reading →

Etrasimod (brand name Velsipity) has been granted marketing authorisation by the European Commission (EC) for use in eligible patients with ulcerative colitis (UC), its manufacturer Pfizer has announced. It is approved to treat patients aged 16 years and older with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biological agent. Continue reading →

Patient cohort description and pathology classification The present study was approved by the Kaunas Regional Biomedical Research Ethics Committee (Protocol No. BE-2-31) and written informed consent was obtained from each subject who participated in the study. All research was performed in accordance with relevant guidelines and regulations.This study consisted of three age- and sex-matched groups (Fig.4) Continue reading →

The NaviCap targeted oral delivery platform, is an ingestible device approximately the size of a fish oil pill. Credit: Andrea Danti via Shutterstock. Therapies within the ulcerative colitis (UC) space are ever-evolving for the improvement of local, targeted therapy. Continue reading →

SAN DIEGO - Biora Therapeutics, Inc. (NASDAQ:BIOR), a biotech firm focused on innovative therapeutic delivery, has announced the completion of the single-ascending dose (SAD) cohorts in its phase 1 clinical trial of BT-600, a novel drug-device combination aimed at treating moderate to severe ulcerative colitis. The company is preparing to commence the multiple-ascending dose (MAD) cohorts in March, with expectations to share SAD data during its corporate update the same month Continue reading →

State Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington Washington D.C. Continue reading →

Active ulcerative colitis patients and normal healthy control individuals The colon tissue samples of 4 active ulcerative colitis patients and 4 normal healthy controls were used to analyze miR-30c and VIP expression levels in this study, which were provided by the First Affiliated Hospital of Bengbu Medical College. The patients were included into this study according to the score of Sutherland Index (to describe the disease activity)37 and the modified Baron score (to represent an endoscopic classification)38. This study was approved by the Ethics Committee of Bengbu Medical College (No.2023LK401) and was conducted in accordance with the ethical guidelines of the Declaration of Helsinki. Continue reading →